Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 2/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 4/20 | 0.41 |
| ▸ | DRD4 | P21917 | 3/20 | 0.41 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12468738 | 0.84 | NPC1 (0.48) | CTSAMAPK14TDP1CNR1MEN1 | |
| SCHEMBL17513656 | 0.83 | MAPK14 (0.45) | MAPK14TDP1CNR1MEN1KMT2A | |
| SCHEMBL10112914 | 0.79 | CTSA (0.53) | CTSAMEN1KMT2A | |
| SCHEMBL17513131 | 0.78 | POLB (0.46) | MAPK14CNR1POLBMEN1KMT2A | |
| SCHEMBL17529439 | 0.76 | CNR1 (0.44) | MAPK14CNR1POLBMEN1KMT2A | |
| SCHEMBL30232755 | 0.75 | CNR1 (0.45) | MAPK14CNR1POLBMEN1KMT2A | |
| SCHEMBL17513666 | 0.75 | CNR1 (0.44) | CNR1MEN1KMT2ACNR2NPC1 | |
| SCHEMBL17513113 | 0.75 | CNR2 (0.47) | MAPK14CNR1POLBCNR2NPC1 | |
| SCHEMBL7107317 | 0.74 | CTSA (0.47) | CTSANPC1RAB9A | |
| SCHEMBL10131089 | 0.73 | SSTR4 (0.46) | CTSAKMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3182962-B1 | COMPOSITIONS AND USES OF AMIDINE DERIVATIVES | BIOCRYST PHARM INC (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-3182962-B1 | COMPOSITIONS AND USES OF AMIDINE DERIVATIVES | BIOCRYST PHARM INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-10905683-B2 | Compositions and uses of amidine derivatives | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-10905683-B2 | Compositions and uses of amidine derivatives | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-20170266172-A1 | Compositions and Uses of Amidine Derivatives | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-09-21 | — | — | US | disclosed |
| US-20170266172-A1 | Compositions and Uses of Amidine Derivatives | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-09-21 | — | — | US | disclosed |
| US-20170266172-A1 | Compositions and Uses of Amidine Derivatives | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-09-21 | — | — | US | disclosed |
| EP-3182962-A1 | COMPOSITIONS AND USES OF AMIDINE DERIVATIVES | Biocryst Pharmaceuticals, Inc. (US) | 2017-06-28 | — | — | EP | disclosed |
| WO-2016029214-A9 | COMPOSITIONS AND USES OF AMIDINE DERIVATIVES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2017-01-05 | — | — | WO | disclosed |
| WO-2016029214-A9 | COMPOSITIONS AND USES OF AMIDINE DERIVATIVES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2017-01-05 | — | — | WO | disclosed |
| WO-2016029216-A2 | METHOD FOR PRODUCING AMIDINE DERIVATIVES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2016-02-25 | — | — | WO | disclosed |
| WO-2016029214-A1 | COMPOSITIONS AND USES OF AMIDINE DERIVATIVES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2016-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10905683-B2 | Compositions and uses of amidine derivatives | HRH3, HRH2, HRH1 | CTSA 1680/4885MAPK14 2569/4885TDP1 2346/4885 |
| US-20170266172-A1 | Compositions and Uses of Amidine Derivatives | HRH3, HRH2, HRH1 | CTSA 1680/4885MAPK14 2569/4885TDP1 2346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.